Literature DB >> 21384218

Trends in classification, referral and treatment and the effect on outcome of patients with glioma: a 20 year cohort.

S C Erridge1, M G Hart, G R Kerr, C Smith, S McNamara, R Grant, A Gregor, I R Whittle.   

Abstract

This retrospective audit was conducted to examine the changes in patient characteristics, referral, treatment and outcome over a 20-year period in a large regional neuro-oncology centre, focusing on the impact of the changes in pathological classification of gliomas. Using the Edinburgh Cancer Centre (ECC) database all cases of glioma were identified and patient, tumour and treatment characteristics noted. Survival was calculated from date of surgery or, if no operation was performed, the date of referral. Comparison was made between four periods 1988-1992 (c1), 1993-1997(c2), 1998-2002(c3) and 2003-2007 (c4). During the 20 years, 1175 patients with a glioma were referred to ECC. The median age increased from 53 years to 57 years (p < 0.001) but the proportion without pathology remained unchanged (10%). The distribution of pathological grades changed over time Grade I-II: 24, 6, 6, and 6%, Grade III: 42, 27, 17, and 13% and Grade IV: 24, 61, 68, and 68% in c1, c2, c3 and c4, respectively (p < 0.001). Immediate RT was given to 68% (c1), 70% (c2), 78% (c3) and 79% (c4). Median interval from resection to RT reduced from 43 days (c1) to 36 days (c4) (p < 0.001). 5-year overall survival for patients with Grade III lesions increased: 21% (c1), 35% (c2), 37% (c3), 33% (c4) as did 1-year overall survival for Grade IV lesions: 18% (c1), 26% (c2), 29% (c3), 27% (c4)). This improvement probably reflects the change in pathological classification rather than a change in management. Proportional hazards analysis of grade IV 1993-2007 only (to reduce pathological variation) showed that younger age, frontal lesions, excision, higher RT dose had reduced hazard of death. Interval from surgery to RT had no impact on survival in this series.

Entities:  

Mesh:

Year:  2011        PMID: 21384218     DOI: 10.1007/s11060-011-0546-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.

Authors:  Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan
Journal:  J Neurooncol       Date:  2007-05-26       Impact factor: 4.130

2.  What will be the radiotherapy machine capacity required for optimal delivery of radiotherapy in Scotland in 2015?

Authors:  Sara C Erridge; Carrie Featherstone; Ruth Chalmers; Jillian Campbell; Diane Stockton; Roger Black
Journal:  Eur J Cancer       Date:  2007-07-05       Impact factor: 9.162

3.  Patterns of care in elderly glioblastoma patients.

Authors:  Fabio M Iwamoto; Anne S Reiner; Katherine S Panageas; Elena B Elkin; Lauren E Abrey
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

4.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

Authors: 
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

5.  A population-based study of glioblastoma multiforme.

Authors:  L Paszat; N Laperriere; P Groome; K Schulze; W Mackillop; E Holowaty
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-09-01       Impact factor: 7.038

6.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Reliability of histological diagnosis including grading in gliomas biopsied by image-guided stereotactic technique.

Authors:  T Revesz; F Scaravilli; L Coutinho; H Cockburn; P Sacares; D G Thomas
Journal:  Brain       Date:  1993-08       Impact factor: 13.501

8.  Age as a predictive factor in glioblastomas: population-based study.

Authors:  Daisuke Kita; Ilja F Ciernik; Salvatore Vaccarella; Silvia Franceschi; Paul Kleihues; Urs M Lütolf; Hiroko Ohgaki
Journal:  Neuroepidemiology       Date:  2009-03-27       Impact factor: 3.282

9.  Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma.

Authors:  Jill S Barnholtz-Sloan; Vonetta L Williams; John L Maldonado; Dilip Shahani; Heather G Stockwell; Marc Chamberlain; Andrew E Sloan
Journal:  J Neurosurg       Date:  2008-04       Impact factor: 5.115

10.  Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment.

Authors:  N G Burnet; R Jena; S J Jefferies; S P Stenning; N F Kirkby
Journal:  Clin Oncol (R Coll Radiol)       Date:  2006-03       Impact factor: 4.126

View more
  6 in total

1.  Surgical treatment of brain tumor coexisted with intracranial aneurysm--case series and review of the literature.

Authors:  Zhihong Zhong; Yuhao Sun; Dong Lin; Qingfang Sun; Liuguan Bian
Journal:  Neurosurg Rev       Date:  2013-05-25       Impact factor: 3.042

Review 2.  Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.

Authors:  Krishanthan Vigneswaran; Stewart Neill; Costas G Hadjipanayis
Journal:  Ann Transl Med       Date:  2015-05

3.  Differentiation of hemangioblastomas from pilocytic astrocytomas using 3-T magnetic resonance perfusion-weighted imaging and MR spectroscopy.

Authors:  D J She; Z Xing; Z Zeng; X Y Shang; D R Cao
Journal:  Neuroradiology       Date:  2014-12-07       Impact factor: 2.804

4.  Novel target for peptide-based imaging and treatment of brain tumors.

Authors:  Maija Hyvönen; Juulia Enbäck; Tuulia Huhtala; Johanna Lammi; Harri Sihto; Janne Weisell; Heikki Joensuu; Katri Rosenthal-Aizman; Samir El-Andaloussi; Ulo Langel; Ale Närvänen; Gabriele Bergers; Pirjo Laakkonen
Journal:  Mol Cancer Ther       Date:  2014-02-03       Impact factor: 6.261

5.  Genome-Wide Analysis for the Regulation of Gene Alternative Splicing by DNA Methylation Level in Glioma and its Prognostic Implications.

Authors:  Zeyuan Yang; Yijie He; Yongheng Wang; Lin Huang; Yaqin Tang; Yue He; Yihan Chen; Zhijie Han
Journal:  Front Genet       Date:  2022-03-04       Impact factor: 4.599

6.  Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain.

Authors:  Jayendrakishore Tanjore Ramanathan; Suvi Lehtipuro; Harri Sihto; József Tóvári; Lilla Reiniger; Vanda Téglási; Judit Moldvay; Matti Nykter; Hannu Haapasalo; Vadim Le Joncour; Pirjo Laakkonen
Journal:  J Cell Mol Med       Date:  2020-05-11       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.